Intrinsic Value of S&P & Nasdaq Contact Us

Exicure, Inc. XCUR NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
43/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$12.00
+203.3%

Exicure, Inc. (XCUR) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 5 Buy, 1 Hold.

The consensus price target is $12.00, representing an upside of 203.3% from the current price $3.96.

Analysts estimate Earnings Per Share (EPS) of $-111.00 and revenue of $0.03B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-4.75 vs est $-111.00 (beat +95.7%). 2025: actual $-0.79 vs est $-78.00 (beat +99%). Analyst accuracy: 0%.

XCUR Stock — 12-Month Price Forecast

$12.00
▲ +203.29% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Exicure, Inc., the price target is $12.00.
The average price target represents a +203.29% change from the last price of $3.96.

XCUR Analyst Ratings

Buy
6
Ratings
5 Buy
1 Hold
Based on 6 analysts giving stock ratings to Exicure, Inc. in the past 3 months
Rating breakdown
Buy
5 83%
Hold
1 17%
83%
Buy
5 analysts
17%
Hold
1 analysts
0%
Sell
0 analysts

EPS Estimates — XCUR

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$4.75 vs Est –$111.00 ▲ 2,236.8% off
2025 Actual –$0.79 vs Est –$78.00 ▲ 9,773.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — XCUR

0%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024 Actual $0.001B vs Est $0.029B ▼ 5,681.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message